{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:38Z","timestamp":1761512738723},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.yebeh.2009.09.003","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T07:36:37Z","timestamp":1255073797000},"page":"521-526","source":"Crossref","is-referenced-by-count":18,"title":["Binasal visual field defects are not specific to vigabatrin"],"prefix":"10.1016","volume":"16","author":[{"given":"Pedro","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme J.","family":"Sills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon N.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2009.09.003_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJM199606133342407","article-title":"New antiepileptic drugs","volume":"334","author":"Dichter","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2009.09.003_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1471-4159.1977.tb10721.x","article-title":"\u0393-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice","volume":"29","author":"Jung","year":"1977","journal-title":"J Neurochem"},{"key":"10.1016\/j.yebeh.2009.09.003_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2009.09.003_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib6","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.09.003_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/019262339001800201","article-title":"Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor","volume":"18","author":"Gibson","year":"1990","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.yebeh.2009.09.003_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1528-1157.2000.tb00134.x","article-title":"The potential for vigabatrin-induced intramyelinic edema in humans","volume":"41","author":"Cohen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2009.09.003_bib10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.09.003_bib11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1528-1167.2007.01133.x","article-title":"Vigabatrin and epilepsy: lessons learned","volume":"48","author":"Wild","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bjo.85.1.110k","article-title":"The wide field multifocal ERG reveals a retinal defect caused by vigabatrin toxicity?","volume":"85","author":"McDonagh","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.yebeh.2009.09.003_bib13","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/01.WNL.0000098938.80082.25","article-title":"Peripheral retinal dysfunction in patients taking vigabatrin","volume":"61","author":"McDonagh","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.09.003_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.yebeh.2009.09.003_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item Quality of Life in Epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/seiz.2000.0397","article-title":"Recovery of visual field constriction following discontinuation of vigabatrin","volume":"9","author":"Krakow","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2009.09.003_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.55.1.40","article-title":"Visual function loss from vigabatrin: effect of stopping the drug","volume":"55","author":"Johnson","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2009.09.003_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1528-1167.2006.00422.x","article-title":"Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose","volume":"47","author":"Kinirons","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2007.01249.x","article-title":"Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy","volume":"49","author":"Conway","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2009.09.003_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioural effects of antiepileptic drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.yebeh.2009.09.003_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/archopht.124.9.1257","article-title":"Short-term treatment of cocaine and\/or methamphetamine abuse with vigabatrin","volume":"124","author":"Fechtner","year":"2006","journal-title":"Arch Ophthalmol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505009005034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505009005034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T23:24:15Z","timestamp":1544916255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505009005034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1525505009005034"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2009.09.003","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}